CNBC
09 Jun 2026, 04:31 UTC · 2h ago
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
Search tags
CNBC
09 Jun 2026, 04:31 UTC · 2h ago
Search tags
Story key points
4 claims · impact-rated
GSK is in talks to acquire oncology biotech Nuvalent for an estimated $9 billion to $10 billion. — A major acquisition at a 29%-43% premium would immediately reprice Nuvalent and signal a significant strategic shift for GSK.
+0.80Nuvalent's lead asset, neladalkib, is currently under FDA review with a decision deadline of November 27. — The success or failure of this regulatory milestone directly determines the fundamental value of the acquisition target.
+0.60Global biotech dealmaking is experiencing a surge, with $106 billion in transactions across 201 deals so far in 2026. — Broad sector momentum suggests a supportive environment for biotech valuations and further consolidation.
+0.40Continue reading
6 related stories
This acquisition would represent a departure from GSK CEO Luke Miels' stated strategy of pursuing smaller deals in the £2 billion to £4 billion range. — Deviation from a stated financial discipline framework can lead to investor concerns regarding overpayment or strategic inconsistency.
Ticker attribution
Model heads
The company is in talks to be acquired at a significant premium of 29% to 43% over its market capitalization.
The company is pursuing a major acquisition to bolster its drug pipeline and address investor concerns.
Mentioned only as a historical reference to a previous asset swap with GSK.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
4h ago
